🧫 Experiment Protocol
ValidationPeriodontitis with intestinal barrier dysfunctionGPR109AC57BL/6J mice with ligature-induced periodontitisproposed
This experiment directly tested the functional role of GPR109A in mediating periodontitis-induced intestinal pathology through pharmacological intervention. Mice with ligature-induced periodontitis were treated with GPR109A modulators: GSK256073 (likely an agonist) and mepenzolate bromide (likely an antagonist or modulator). The study evaluated the effects of GPR109A activation/inhibition on tight junction integrity, intestinal barrier function, and both local and systemic inflammatory responses. This pharmacological approach provided direct functional validation of GPR109A's role in the periodontitis-gut inflammation axis and tested the therapeutic potential of targeting this receptor.
PRIMARY OUTCOME
Tight junction integrity and inflammatory cytokine levels
EXPECTED OUTCOMES
GPR109A activation would reverse barrier disruption and reduce inflammation
SUCCESS CRITERIA
Significant improvement in tight junction integrity and reduction in pro-inflammatory cytokines with GPR109A activation
PROTOCOL
Administration of GPR109A modulators (GSK256073 and mepenzolate bromide) to periodontitis mice, followed by assessment of barrier function and inflammatory markers